(BPT) – When Navy vet Terry O’Keefe first started to get sick, he was enjoying his retirement, touring the U.S. in an R.V. with his wife, Diane. At first, the couple thought that Terry just had ...

On Tuesday, the FDA approved NovoCure’s (NASDAQ:NVCR) Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or docetaxel for adult patients with metastatic non-small cell lung cancer (mNSCLC) who ...

The FDA has granted approval for Novocure‘s wearable medical device, Optune Lua, designed to treat advanced non-small cell lung cancer (NSCLC). The device utilizes portable transducer arrays placed on ...

Optune Lua is now approved for use concurrently with immune checkpoint inhibitors or docetaxel in adult patients with metastatic NSCLC who have progressed on or after a platinum-based regimen CE Mark ...

(RTTNews) - Novocure (NVCR) announced that Japan's Ministry of Health, Labour and Welfare approved Optune Lua for concurrent use with PD-1/PD-L1 inhibitors for the treatment of adult patients with ...

(1) Optune Lua includes both active patients in NSCLC and MPM. Worldwide, there were 43 and 25 active MPM patients on therapy as of June 30, 2025 and 2024 and 94 and 1 active NSCLC patient(s) on ...

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today reported preliminary unaudited financial and operational results for the quarter and full year ended December 31, 2024. Novocure is a ...

Optune Lua adoption lag hit shares, but 2026 catalysts and $230M net cash could drive a rebound. Know more about NVCR stock here.

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today reported financial results for the quarter and full year ended December 31, 2024. Novocure is a global oncology company working to ...

(1) Optune Lua includes both active patients in NSCLC and MPM. Worldwide, there were 39 and 32 active MPM patients on therapy as of September 30, 2025 and 2024 and 100 and 1 active NSCLC patient(s) on ...